Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Invested Capital (2016 - 2026)

United Therapeutics' Invested Capital history spans 17 years, with the latest figure at $7.1 billion for Q4 2025.

  • On a quarterly basis, Invested Capital rose 5.22% to $7.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 billion, a 5.22% increase, with the full-year FY2025 number at $7.1 billion, up 5.22% from a year prior.
  • Invested Capital hit $7.1 billion in Q4 2025 for United Therapeutics, up from $6.6 billion in the prior quarter.
  • Over the last five years, Invested Capital for UTHR hit a ceiling of $7.2 billion in Q2 2025 and a floor of $3.4 billion in Q1 2021.
  • Historically, Invested Capital has averaged $5.4 billion across 5 years, with a median of $5.6 billion in 2023.
  • Biggest five-year swings in Invested Capital: surged 33.11% in 2023 and later rose 1.37% in 2025.
  • Tracing UTHR's Invested Capital over 5 years: stood at $4.0 billion in 2021, then increased by 21.16% to $4.8 billion in 2022, then soared by 33.11% to $6.4 billion in 2023, then increased by 5.63% to $6.7 billion in 2024, then rose by 5.22% to $7.1 billion in 2025.
  • Business Quant data shows Invested Capital for UTHR at $7.1 billion in Q4 2025, $6.6 billion in Q3 2025, and $7.2 billion in Q2 2025.